Featured article

Could New Hepatitis B Drug – Bepirovirsen – Offer a Higher Functional Cure Rate?

At the start of January, pharmaceutical company GSK announced positive results from its two phase-III trials for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B. They claim that bepirovirsen …

Community

‘Shared decision-making’ for childhood vaccines sounds empowering – but it may mean less access for families already stretched thin

Shared decision-making is an approach doctors use when there’s genuinely more than one reasonable choice and the answer depends on what matters most and feels right to the patient.

Why the Hepatitis B Birth Dose Matters

Hepatitis B vaccination within the first 24 hours has been part of Australia’s National Immunisation Program for 25 years, helping to reduce hepatitis B in the Australian population.
More from Community

Living with Hepatitis

Curing Hepatitis C Reduces Strain on the Immune System of HIV Patients

Fighting two infections at once puts an extra-heavy burden on the immune system. In Australia for example, a number of older people with haemophilia live with both hepatitis C and …

Wait! There’s more…

Hepatitis is not often seen as a health issue for children – but as shown in Community News #107, children can be at risk of hepatitis or hepatitis-related health issues …
More from Living with Hepatitis

Policies & Research

Pages of clinicians and researchers statement showing names and logos

Hepatitis Experts Welcome ATAGI Statement on Hepatitis B Birth Dose Vaccination

Australia’s hepatitis experts have welcomed a new statement from the Australian Technical Advisory Group on Immunisation (ATAGI) confirming the importance and safety of administering the hepatitis B vaccine at birth. Responding to …

Abandoning Hepatitis B Vaccines for Babies is Bad Science and Bad Medicine

Hepatitis Australia, ASHM and the Australian Technical Group on Immunisation (ATAGI) are urging Australians to maintain routine hepatitis B vaccinations for newborns following the alarming news that the advisory panel …
More from Policies & Research

Resources

In Our Library: October 2025 Highlights

HepSA Library October acquisition highlights: HBV surveillance, managing hep B, hep D advances, and more…

Understanding Clinical Trials in MASLD

Involvement in a clinical trial may provide access to new treatments and provide participants with a higher level of clinical care, which many people with fatty liver find beneficial.
More from Resources